AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32174840
Drug: No asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No asthma treatment
Trial: 32175519
Drug: small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small-quantity lipid-based nutrition supplement (LNS) containing >20 micronutrients
Trial: 32175617
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor T-cell therapies (CAR T-cells)
Trial: 32175617
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation trials
Trial: 32175969
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of adverse drug events (ADEs) by clinical pharmacists through structured interviews and medication history collection.
Trial: 32176787
Drug: Imipenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (1 g mixed with 200 mL normal saline, infused intravenously over 3 hours at 8-hour intervals, concentration 5 mg/mL, rate of infusion 5.5 mg/min)
Trial: 32178626
Drug: L-arginine/ADMA ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine/ADMA ratio assessment at 4-24 hours after surgery
Trial: 32178676
Drug: Polyacrylamide gel
RxNorm normalized name: polyacrylamide (10000 MW)
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyacrylamide gel electrophoresis Lipoprint© System for lipoprotein profile analysis
Trial: 32179633
Drug: Spartalizumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab (1, 3, or 10 mg/kg Q2W; 3 or 5 mg/kg Q4W)
Trial: 32182364
Drug: Intralesional rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intralesional rituximab (4 weekly injections followed by 6 monthly injections)
Trial: 32182791
Drug: Everolimus at
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus at 10 mg/day
Trial: 32182791
Drug: Everolimus at
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus at 10 mg/day with octreotide LAR at 30 mg/month (18 patients)
Trial: 32182949
Drug: Curative intent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curative intent radiotherapy with or without androgen deprivation therapy (ADT)
Trial: 32183229
Drug: Zebrafish avatar
RxNorm normalized name: ZINC OXIDE 20 g in 100 g TOPICAL LOTION [avatara Kom Bu Cha The Simple Shield Balancing Oil-Free Moisturizer SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zebrafish avatar model for drug efficacy studies
Trial: 32183229
Drug: Chemotherapy dose
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy dose conversion formula
Trial: 32184653
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic treatment (SAT; IV paracetamol 1g or ketoprofen 100mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Trial: 32185745
Drug: Repository Corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository Corticotropin Injection (RCI) 80 U twice weekly for 12 weeks
Trial: 32186413
Drug: Herbal Medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal Medicine SH003
Trial: 32187112
Drug: BUP-XR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR treatment duration >12 months
Trial: 32187112
Drug: BUP-XR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR treatment duration ≤2 months
Trial: 32187112
Drug: BUP-XR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-XR treatment
Trial: 32187457
Drug: Selumetinib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (25 mg/m², oral, twice daily, continuous dosing schedule, 28-day cycles)
Trial: 32187883
Drug: Clofarabine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofarabine (30 mg/m²)
Trial: 32188417
Drug: NEPA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA and dexamethasone (12 mg intravenously)
Trial: 32188593
Drug: Omega-3 supplement
RxNorm normalized name: Systane Vitamin Omega-3 Supplement Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplement (4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) as ethyl esters)
Trial: 32188593
Drug: Placebo (4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g/day olive oil)
Trial: 32188704
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg administered intravenously every 21 days
Trial: 32188971
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LFA and β-D-glucan test
Trial: 32190892
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sufficient 25(OH)D3 (≥50 nmol/L) and high magnesium intake
Trial: 32191209
Drug: Hypothermic oxygenated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic oxygenated perfusion (HOPE) with cold Belzer solution (4-10°C) and continuous oxygenation (partial pressure of oxygen of 500-600 mm Hg)
Trial: 32191209
Drug: Static cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static cold storage (SCS) with Celsior solution stored on ice
Trial: 32191330
Drug: Apatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib plus oral vinorelbine
Trial: 32192431
Drug: cis-atracurium 150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-atracurium 150, 100, 70, 50, 30, and 20 μg·kg
Trial: 32192445
Drug: Novel test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel test for assessing the effect of genetic markers on drug immunogenicity
Trial: 32192445
Drug: Novel test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel test for analyzing drug immunogenicity
Trial: 32192573
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day cycle (part A)
Trial: 32192573
Drug: Nivolumab (recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (recommended phase 2 dose) (part B)
Trial: 32192746
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at 12 months
Trial: 32195186
Drug: Triplet combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet combination of Trastuzumab, Lapatinib, and Chemotherapy
Trial: 32195932
Drug: Drug-eluting beads
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting beads transarterial chemoembolization (DEB-TACE)
Trial: 32197630
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous MSCs (0.5-2 × 10^6 cells) after surgical scar resection
Trial: 32197630
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous MSCs
Trial: 32200083
Drug: Physicians' meetings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians' meetings to optimize bowel preparation
Trial: 32200083
Drug: Written and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written and oral instructions to patients
Trial: 32200083
Drug: Split-dose regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose regimens
Trial: 32200083
Drug: 75% or
RxNorm normalized name: Cellulose 75% Oral Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% or more intake of bowel preparation
Trial: 32200083
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of anti-psychotic drugs
Trial: 32200138
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg daily until radiological progression or death
Trial: 34763195
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg daily
Trial: 32201506
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg orally twice daily, days 1-5 and 8-12) and Bevacizumab (5 mg/kg intravenously, day 1) every 2 weeks
Trial: 32202706
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily sitting
Trial: 32202706
Drug: Daily sedentary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sedentary time (accelerometer subsample)
Trial: 32203069
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg daily for 4-12 weeks
Trial: 32203069
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg daily for >50 days
Trial: 32203268
Drug: Treosulfan-based conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan-based conditioning treatment
Trial: 32203698
Drug: Pemigatinib 13.5
RxNorm normalized name: pemigatinib 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib 13.5 mg orally once daily (21-day cycle; 2 weeks on, 1 week off)
Trial: 32205016
Drug: Capivasertib (AZD5363)
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib (AZD5363) 320 mg, 400 mg, and 480 mg twice daily (b.i.d.) for 4 days on and 3 days off in combination with enzalutamide 160 mg daily
Trial: 32205016
Drug: Capivasertib (AZD5363)
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib (AZD5363) 400 mg b.i.d. with enzalutamide 160 mg daily
Trial: 32205017
Drug: Ipatasertib 600
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 600 mg combined with paclitaxel
Trial: 32205017
Drug: Ipatasertib 600
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 600 mg combined with mFOLFOX6
Trial: 32205017
Drug: Ipatasertib 400
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 400 mg combined with paclitaxel
Trial: 32205017
Drug: Ipatasertib combined
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib combined with chemotherapy or hormonal therapy
Trial: 32205128
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser therapy using a 400-μm optical fiber with a 1470-nm laser
Trial: 32205328
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor therapy
Trial: 32206659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pulmonary recruitment maneuver and intraperitoneal bupivacaine
Trial: 32206660
Drug: Oxaloacetate/vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaloacetate/vitamin C (2 capsules of 100 mg oxaloacetate/150 mg ascorbic acid)
Trial: 32206660
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules of rice flour)
Trial: 32206673
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis)
Trial: 32206973
Drug: Adalimumab therapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab therapy for 24 months
Trial: 32206976
Drug: Concurrent scalp-sparing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent scalp-sparing radiation (60 Gy in 30 fractions) with standard concurrent temozolomide (75 mg/m2) and tumor treatment fields (TTFields)
Trial: 32207164
Drug: Imalumab (oxMIF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imalumab (oxMIF inhibitor) at doses of 1 to 50 mg/kg IV every 2 weeks or 10 or 25 mg/kg IV weekly (1 cycle = 28 days)
Trial: 32208121
Drug: Therapeutic adjustment
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic adjustment or treatment switch after pathological ABPM.
Trial: 32208121
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of antihypertensive therapy after pathological ABPM.
Trial: 32208873
Drug: Molecularly matched
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly matched therapy
Trial: 32208957
Drug: Ivosidenib (AG-120)
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivosidenib (AG-120) monotherapy
Trial: 32209624
Drug: Current systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current systemic or topical treatment for AD (at the discretion of the investigator)
Trial: 32210458
Drug: Pre-treatment CD4+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment CD4+ count <350 cells/mm3
Trial: 32210527
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravitreal aflibercept (IVT-AFL) every 4 weeks (2q4)
Trial: 32210527
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravitreal aflibercept (IVT-AFL) every 8 weeks (2q8)
Trial: 32210527
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravitreal aflibercept (IVT-AFL)
Trial: 32210906
Drug: Nilvadipine (dihydropyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (dihydropyridine calcium channel blocker)
Trial: 32211336
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate 300 mg given 2-3 times daily, adjusted to target serum concentration (0.6 to 1.0 mmol/L); Tretinoin 22.5 or 45 mg/m²
Trial: 32211756
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of ceftolozane/tazobactam administered q8h
Trial: 37154471
Drug: Crisaborole ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole ointment, 2%, applied twice daily for 28 days
Trial: 32213344
Drug: Melflufen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melflufen plus dexamethasone (40 mg melflufen, 40 mg dexamethasone weekly)
Trial: 32213344
Drug: Single-agent melflufen
RxNorm normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent melflufen
Trial: 32214793
Drug: 0.19 mg
RxNorm normalized name: zinc oxide 0.19 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.19 mg Fluocinolone Acetonide intravitreal implant
Trial: 32217877
Drug: Patient-reported outcome
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported outcome measures (PROMs) including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Outcomes and Experiences Questionnaire
Trial: 32218807
Drug: Apatinib (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (first line, second line, and third or higher line therapy)
Trial: 32218807
Drug: Apatinib (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (low-dose 250 mg, mid-dose 425-500 mg, high-dose 675-850 mg)
Trial: 32219330
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (MET)
Trial: 32219330
Drug: Nonpharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological treatment (NPT)
Trial: 32219421
Drug: Maternal fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal fasting glucose increase (1-mmol/L)
Trial: 32219421
Drug: Maternal 2-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal 2-h OGTT glucose increase (1-mmol/L)
Trial: 32219431
Drug: Hydrocodone-acetaminophen prescribed
RxNorm normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen prescribed (median 12 pills)
Trial: 32220908
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle until disease progression, death, or unacceptable toxicity.
Trial: 32221013
Drug: Haploidentical NK
RxNorm normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical NK cell infusion
Trial: 32221099
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of opioids during RSI in adults
Trial: 32221099
Drug: First-line medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line medications for haemodynamically stable adults: propofol
Trial: 32221099
Drug: First-line medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line medications for haemodynamically stable adults: suxamethonium
Trial: 32221099
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of opioids during RSI in paediatric patients
Trial: 32221099
Drug: First-line medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line medications for haemodynamically stable children: propofol
Trial: 32221099
Drug: First-line medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line medications for haemodynamically stable children: rocuronium
Trial: 32222808
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin (pola) 1.0-1.8 mg/kg administered intravenously every 3 weeks (q3w) with R/G-CHP
Trial: 32223740
Drug: mNavigator digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mNavigator digital health application for protocol compliance in pediatric cancer treatment
Trial: 32223937
Drug: Larotrectinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotrectinib (oral TRK inhibitor)
Trial: 32224030
Drug: Non-Glycoprotein IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Glycoprotein IIb/IIIa inhibitors (non-GPI)
Trial: 32224306
Drug: Lurbinectedin (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin (3.2 mg/m²)
Trial: 32224416
Drug: Toripalimab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (10 mg/kg Q2W)
Trial: 32225136
Drug: MS-Fit training
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-Fit training program (standardized, ambulatory, hospital-based circuit training) performed two hours, twice weekly, for two months.
Trial: 32226634
Drug: Client-centred lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centred lifestyle and behavioural intervention, details on dosage and duration not specified.
Trial: 32227570
Drug: Weekly prophylaxis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly prophylaxis, modified prophylaxis, or episodic treatment
Trial: 32228297
Drug: Progression group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progression group (AAA with >10-mL increase in volume)
Trial: 32228297
Drug: Stable group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable group (AAA with ≤10-mL increase in volume)
Trial: 32231633
Drug: Conventional bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional bone conduction hearing implant system
Trial: 32231633
Drug: Less invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less invasive treatment with new abutment technology
Trial: 32232107
Drug: Microcurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent treatment administered at home for 5 mins daily for 4 weeks.